Last updated
  • 3-{2-[cyclopropyl(methyl)amino]ethyl}-1H-indol-4-ol
PubChem CID
Chemical and physical data
Formula C14H18N2O
Molar mass 230.306 g·mol−1
3D model (JSmol)
  • Oc3cccc2ncc(CCN(C)C1CC1)c23
  • InChI=1S/C14H26N2O/c1-16(11-5-6-11)8-7-10-9-15-12-3-2-4-13(17)14(10)12/h10-15,17H,2-9H2,1H3

4-HO-McPT (4-hydroxy-N-methyl-N-cyclopropyltryptamine) is a psychedelic tryptamine derivative. It has serotonergic effects, [1] and has reportedly been sold as a designer drug since around 2016, but was not definitively identified by forensic laboratories until 2018. [2] [3] It is illegal in Finland. [4]

See also

Related Research Articles

4-HO-DiPT Chemical compound

4-Hydroxy-N,N-diisopropyltryptamine is a synthetic psychedelic drug. It is a higher homologue of psilocin, 4-HO-DET, and is a positional isomer of 4-HO-DPT and has a tryptamine molecular sub-structure.

Diisopropyltryptamine Chemical compound

Diisopropyltryptamine is a psychedelic hallucinogenic drug of the tryptamine family that has a unique effect. While the majority of hallucinogens affect the visual sense, DiPT is primarily aural.

Diethyltryptamine Chemical compound

DET, also known under its chemical name N,N-diethyltryptamine and as T-9, is a psychedelic drug closely related to DMT and 4-HO-DET. However, despite its structural similarity to DMT, its activity is induced by an oral dose of around 50–100 mg, without the aid of MAO inhibitors, and the effects last for about 2–4 hours.

4-HO-MiPT Chemical compound

4-HO-MiPT is a synthetic substituted aromatic compound and a lesser-known psychedelic tryptamine. It is thought to be a serotonergic psychedelic, similar to magic mushrooms, LSD and mescaline. Its molecular structure and pharmacological effects somewhat resemble those of the tryptamine psilocin, which is the primary psychoactive chemical in magic mushrooms.


5,N-Dimethyl-N-isopropyltryptamine (5-Me-MiPT) is a tryptamine derivative that is thought to be a psychedelic drug. It was first made in 1989. In vitro binding experiments on brain homogenates showed it to have serotonin receptor binding affinity between that of MiPT and 5-MeO-MiPT, both of which are known to be active psychedelics in humans.

Aeruginascin Chemical compound

Aeruginascin or N,N,N-trimethyl-4-phosphoryloxytryptamine is an indoleamine derivative which occurs naturally within the mushroom Inocybe aeruginascens and Pholiotina cyanopus. Aeruginascin is the N-trimethyl analogue of psilocybin. It is closely related to the frog skin toxin bufotenidine (5-HTQ), a potent 5-HT3 receptor agonist, but the aeruginascin metabolite 4-HO-TMT shows strong binding at the 5-HT2 receptors similar to psilocin. The first scientific literature about the pharmacological effects of aeruginascin is from a study published by Gartz in 1989. Across 23 analyzed cases of accidental hallucinogenic mushroom poisonings, people who had ingested the mushroom Inocybe aeruginascens reported only euphoric experiences. This is in contrast to the slight and in some cases extremely dysphoric experiences reported from the accidental ingestion of non aeruginascin containing mushrooms (containing solely psilocybin and psilocin).

4-HO-MPMI Chemical compound

4-HO-MPMI is a tryptamine derivative that is a psychedelic drug. It was developed by the team led by David Nichols from Purdue University in the late 1990s. This compound produces hallucinogen-appropriate responding in animal tests with a similar potency to the amphetamine-derived psychedelic DOI, and has two enantiomers, with only the (R)-enantiomer being active.

The molecular formula C14H18N2O may refer to:

5-Ethoxy-DMT Chemical compound

5-Ethoxy-DMT is a tryptamine derivative which has been previously synthesized as a chemical intermediate, but has not been studied to determine its pharmacology.

4-HO-DSBT Chemical compound

4-HO-DsBT (4-hydroxy-N,N-di-sec-butyltryptamine) is a tryptamine derivative which acts as a serotonin receptor agonist. It was first made by Alexander Shulgin and is mentioned in his book TiHKAL, but was never tested by him. However it has subsequently been tested in vitro and unlike the n-butyl and isobutyl isomers which are much weaker, the s-butyl derivative retains reasonable potency, with a similar 5-HT2A receptor affinity to MiPT but better selectivity over the 5-HT1A and 5-HT2B subtypes.


5-HO-DiPT (5-hydroxy-N,N-di-iso-propyltryptamine) is a tryptamine derivative which acts as a serotonin receptor agonist. It is primarily known as a metabolite of the better known psychoactive drug 5-MeO-DiPT, but 5-HO-DiPT has also rarely been encountered as a designer drug in its own right. Tests in vitro show 5-HO-DiPT to have high 5-HT2A affinity and good selectivity over 5-HT1A, while being more lipophilic than the related drug bufotenine (5-HO-DMT), which produces mainly peripheral effects.


5-MeO-DiBF is a psychedelic that has been sold online as a designer drug and was first definitively identified in December 2015 by a forensic laboratory in Slovenia. It is thought to act as an agonist for the 5-HT1A and 5-HT2 family of serotonin receptors. It is related in structure to the psychedelic tryptamine derivative 5-MeO-DiPT, but with the indole nitrogen replaced by oxygen, making 5-MeO-DiBF a benzofuran derivative. It is several times less potent as a serotonin agonist than 5-MeO-DiPT and with relatively more activity at 5-HT1A, but still shows strongest effects at the 5-HT2 family of receptors.

3-HO-PCP Chemical compound

3-Hydroxyphencyclidine (3-HO-PCP) is a dissociative of the arylcyclohexylamine class related to phencyclidine (PCP) that has been sold online as a designer drug.

4-HO-McPeT Chemical compound

4-HO-McPeT (4-hydroxy-N-methyl-N-cyclopentyltryptamine) is a tryptamine derivative which has serotonergic effects.


5-MeO-EPT is a psychedelic tryptamine derivative which has been sold as a designer drug.


5-MeO-MET (5-Methoxy-N-methyl-N-ethyltryptamine) is a relatively rare designer drug from the substituted tryptamine family, related to compounds such as N-methyl-N-ethyltryptamine and 5-MeO-DMT. It was first synthesised in the 1960s and was studied to a limited extent, but was first identified on the illicit market in June 2012 in Sweden. It was made illegal in Norway in 2013, and is controlled under analogue provisions in numerous other jurisdictions.

<i>N</i>-<i>t</i>-Butyltryptamine Chemical compound

N-t-Butyltryptamine (NTBT) is a tryptamine derivative which has serotonergic effects. It is described by Alexander Shulgin as producing "a light-headed intoxication that is a totally pleasant buzz, but nothing more profound than that" at a dosage range of 5 to 20 mg, along with the related sec-butyl isomer NSBT which is similar in effects but slightly less potent.


O-Acetylbufotenine is a tryptamine derivative which produces psychedelic-appropriate responding in animal studies. It is an acylated derivative of bufotenine with higher lipophilicity that allows it to cross the blood-brain barrier; once inside the brain, it is metabolised to bufotenine. It also acts directly as an agonist at 5-HT1A and 5-HT1D receptors.


  1. USapplication 2019142851,Chadeayne, Andrew R,"Compositions comprising a psilocybin derivative and a cannabinoid",published 2019-05-16, assigned to CaaMTech LLC, now abandoned.
  2. Chapman SJ (March 2018). "PeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra". Blotter. 3 (1). doi: 10.16889/isomerdesign-5 .
  3. "Analytical Report: 4-HO-McPT" (PDF). Nacionalni Forenzični Laboratorij. Slovenia. September 2018.
  4. Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista